Welcome to our dedicated page for iTeos Therapeutics news (Ticker: ITOS), a resource for investors and traders seeking the latest updates and insights on iTeos Therapeutics stock.
iTeos Therapeutics, Inc. (NASDAQ: ITOS) is a clinical-stage biopharmaceutical company committed to enhancing the lives of cancer patients through innovative immunotherapies. Founded in 2012 and headquartered in Gosselies, Belgium, with a research center in Watertown, Massachusetts, iTeos leverages deep insights into tumor immunology and immunosuppressive pathways to design novel product candidates.
The company's pipeline includes several promising drug candidates:
- EOS-200271: A potent and selective IDO1 inhibitor with exceptional brain penetration, currently in clinical stages.
- EOS-100850 (Inupadenant): An insurmountable adenosine A2A receptor antagonist designed to inhibit the ATP-adenosine pathway. This therapeutic candidate is in Phase 2 studies, targeting high adenosine concentrations in solid tumors.
- EOS-884448 (Belrestotug): An anti-TIGIT antibody developed to enhance the anti-tumor immune response. This candidate is being progressed in multiple indications in collaboration with GSK and is currently in Phase 1 trials.
- EOS-984: A first-in-class small molecule aimed at inhibiting the immunosuppressive activity of adenosine. This candidate is in Phase 1 development, with studies showing potential synergy with Inupadenant.
iTeos is supported by the Ludwig Institute for Cancer Research, the Walloon Region of Belgium, and the European Fund for Economic and Regional Development (FEDER). Notably, the company has secured a partnership with GSK to develop the TIGIT:PD-1 doublet therapy, which has the potential to become a leading treatment in the immuno-oncology field.
For the latest updates and detailed information, visit the 'Investors' section of their website at www.iteostherapeutics.com.
iTeos Therapeutics (ITOS) reported its financial results for Q4 and FY 2022, highlighting a cash balance of $731.4 million, expected to support operations into 2026. The company is progressing with 10 clinical trials, notably the anti-TIGIT monoclonal antibody EOS-448 in collaboration with GSK, and the inupadenant program targeting the adenosine pathway. Net income for Q4 2022 was $20.5 million with EPS of $0.57, down from the previous year, reflecting increased R&D expenses of $25.4 million and G&A expenses of $11.1 million.
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a biopharmaceutical company focused on immuno-oncology, has announced that CEO Michel Detheux will present at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, at 9:10 a.m. ET. A live webcast of the presentation will be accessible on the company's Investors webpage, with a replay available for 30 days. iTeos is advancing innovative therapies aimed at enhancing immune responses against cancer, including EOS-448 and inupadenant. These programs target novel immuno-oncology pathways, reflecting the company’s commitment to improving clinical outcomes.
iTeos Therapeutics, Inc. (Nasdaq: ITOS), a biopharmaceutical company focused on immuno-oncology therapies, has announced that its CEO, Michel Detheux, will present at the SVB Securities Global Biopharma Conference on February 14, 2023, at 10:00 a.m. EST. A live webcast of the presentation will be accessible on the company's website, with an archived replay available for 30 days post-event.
iTeos is developing innovative therapies, including EOS-448, an anti-TIGIT antibody in collaboration with GSK, and inupadenant, an adenosine A2A receptor antagonist entering proof-of-concept trials, targeting cancer immunosuppression.
FAQ
What is the current stock price of iTeos Therapeutics (ITOS)?
What is the market cap of iTeos Therapeutics (ITOS)?
What does iTeos Therapeutics, Inc. do?
What are the key products in iTeos' pipeline?
Where is iTeos Therapeutics headquartered?
What is EOS-200271?
What is Inupadenant (EOS-100850)?
Who are iTeos' key partners?
What is EOS-884448 (Belrestotug)?
What is EOS-984?
Where can I find the latest news about iTeos Therapeutics?
